Skip to main content
Premium Trial:

Request an Annual Quote

Abaxis, LamdaGen Teaming Up to Combine POC Platform with Plasmon Resonance Biosensing

Premium

Point-of-care device manufacturer Abaxis and biosensor firm LamdaGen said this week that they have entered into an R&D agreement aiming to integrate LamdaGen's plasmonic ELISA technology on Abaxis's rotor-based POC platforms.

If the integration proves viable, the agreement would enable Abaxis to multiplex a variety of markers on its rotor-based system, Abaxis CEO Clint Severson said in a statement.

"Both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," he said. "The ability to unify both diagnostic systems
onto our existing rotor will greatly expand Abaxis’ global diagnostic offerings.”

LamdaGen's biosensor platform is based on localized surface plasmon resonance, offering quantitative results and detection levels in the femtomolar range.

Financial and other terms of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more